If you're looking for more information on Cannabidiol (CBD) and Potential Therapeutic Benefits Relating to Issues with Sleep, Anxiety, Headaches, Migraines, Hangovers, Arthritis, Allergies we Highly Recommend checking the Source of the Cited Articles. Go to the Source and Learn More. We all are! www.pubmed.gov
Bih, C.I., et al., Molecular Targets of Cannabidiol in Neurological Disorders. Neurotherapeutics, 2015. 12(4): p. 699-730. https://www.ncbi.nlm.nih.gov/pubmed/26264914
Machado Bergamaschi, M., et al., Safety and Side Effects of Cannabidiol, a Cannabis Sativa Constituent. https://www.ncbi.nlm.nih.gov/pubmed/22129319 Current Drug Safety, 2011. 6(4): p. 237-249.
Marks, M.D., et al., Identification of candidate genes affecting Δ(9)- tetrahydrocannabinol biosynthesis in Cannabis sativa. Journal of Experimental Botany, 2009. 60(13): p. 3715-3726. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736886/
Jiang, R., et al., Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sci, 2011. 89(5-6): p. 165-70. https://www.ncbi.nlm.nih.gov/pubmed/21704641
Cunetti, L., et al., Chronic pain treatment with cannabidiol in kidney transplant patients in Uruguay. Transplant Proc, 2018. 50(2): p. 461-464 https://www.ncbi.nlm.nih.gov/pubmed/29579828
Hundal, H., et al., The effects of cannabidiol on persecutory ideation and anxiety in a high trait paranoid group. J Psychopharmacol, 2018. 32(3): p. 276-282. https://www.ncbi.nlm.nih.gov/pubmed/29086614
Pisanti, S., et al., Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacol Ther, 2017. 175: p. 133-150 https://www.ncbi.nlm.nih.gov/pubmed/28232276
Devinsky, O., et al., Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia, 2014. 55(6): p. 791-802 https://www.ncbi.nlm.nih.gov/pubmed/24854329
Irving, P.M., et al., A randomized, double-blind, placebo-controlled, parallel-group, pilot study of cannabidiol-rich botanical extract in the symptomatic treatment of ulcerative colitis. Inflamm Bowel Dis, 2018. 24(4): p.714-724 https://www.ncbi.nlm.nih.gov/pubmed/29538683
https://www.who.int/medicines/access/controlled-substances/CannabidiolCriticalReview.pdf
June 26th, 2018 - FDA Approved Epidiolex - Created and Sold by GW Pharmaceutical
https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms
Fasinu, P.S., et al., Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents. Pharmacotherapy, 2016. 36(7): p. 781-796 https://www.ncbi.nlm.nih.gov/pubmed/27285147
Iffland, K. and F. Grotenhermen, An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. Cannabis and Cannabinoid Research, 2017. 2(1): p. 139-154 https://www.ncbi.nlm.nih.gov/pubmed/28861514
Pertwee, R., The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐ tetrahydrocannabivarin. British journal of pharmacology, 2008. 153(2): p. 199-215 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2219532/
McPartland, J.M., et al., Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. British Journal of Pharmacology, 2015. 172(3): p. 737-753 https://www.ncbi.nlm.nih.gov/pubmed/25257544
